{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T21:08:08Z","timestamp":1770757688026,"version":"3.50.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T00:00:00Z","timestamp":1458691200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T00:00:00Z","timestamp":1458691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U10DA013045"],"award-info":[{"award-number":["U10DA013045"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Indivior, Inc"},{"name":"Alkermes, Inc"},{"name":"Braeburn Pharm, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11481-016-9663-z","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T05:57:49Z","timestamp":1458712669000},"page":"394-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here"],"prefix":"10.1007","volume":"11","author":[{"given":"Walter","family":"Ling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,23]]},"reference":[{"key":"9663_CR1","volume-title":"The Axemaker\u2019s Gift","author":"J Burke","year":"1997","unstructured":"Burke J, Orenstein R (1997) The Axemaker\u2019s Gift. Tarcher\/Putnam, New York"},{"key":"9663_CR2","unstructured":"Chalk M, Baser O, Halpern R, Gastfriend DR (2011) Healthcare cost outcomes for alcohol dependence: A comparison of four treatments. Presented at American Society of Addiction Medicine 42nd Annual Medical-Scientific Conference, Washington, DC"},{"issue":"5","key":"9663_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5055\/jom.2005.0054","volume":"1","author":"R Colquhoun","year":"2005","unstructured":"Colquhoun R, DY T, Hull S (2005) A comparison of oral and implant naltrexone outcomes at 12\u00a0months. J Opioid Manag 1(5):249\u2013256","journal-title":"J Opioid Manag"},{"key":"9663_CR4","doi-asserted-by":"crossref","unstructured":"Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW (2002) Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 159(4):351\u2013360. Epub 2001 Nov 1","DOI":"10.1007\/s002130100909"},{"key":"9663_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O\u2019Brien CP (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry 63:210\u2013218","journal-title":"Arch Gen Psychiatry"},{"key":"9663_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","volume":"193","author":"VP Dole","year":"1965","unstructured":"Dole VP, Nyswander ME (1965) A medical treatment for diacetyl-morphine (heroin) addiction. JAMA 193:646","journal-title":"JAMA"},{"key":"9663_CR7","doi-asserted-by":"crossref","unstructured":"Doran C, Shanahan M, Mattick R, Ali R, White J, Bell J (2007) Buprenorphine versus methadone maintenance: a cost-effectiveness analysis, Drug Alcohol Depend, volume 71, issue 3, 10 September 2003, pages 295\u2013302","DOI":"10.1016\/S0376-8716(03)00169-8"},{"key":"9663_CR8","doi-asserted-by":"crossref","unstructured":"Fiellin, DA (2007)The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med 1(2):62\u201367.","DOI":"10.1097\/ADM.0b013e3180473c11"},{"key":"9663_CR9","unstructured":"Fletcher, AM, Inside Rehab (2013) New York: Penguin Group"},{"issue":"10","key":"9663_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D (2003) Buprenorphine\/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349(10):949\u2013958","journal-title":"N Engl J Med"},{"key":"9663_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0376-8716(00)00211-8","volume":"62","author":"M Gossop","year":"2001","unstructured":"Gossop M, Marsden J, Stewart D, Treacy S (2001) Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 62:255\u2013264","journal-title":"Drug Alcohol Depend"},{"key":"9663_CR12","unstructured":"Green P. (2010) Outpatient drug utilization trends for buprenorphine years 2002\u20132009. buprenorphine.samhsa.gov\/bwns\/2010...pdf\/09_Greene_508.pdf"},{"key":"9663_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1176\/appi.ps.55.3.221","volume":"55","author":"KM Harris","year":"2004","unstructured":"Harris KM, DeVries A, Dimidjian K (2004) Datapoints: Trends in naltrexone useamong members of a large private health plan. Psychiatr Serv 55:221","journal-title":"Psychiatr Serv"},{"key":"9663_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","volume":"35","author":"DR Jasinski","year":"1978","unstructured":"Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmscology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501\u2013516","journal-title":"Arch Gen Psychiatry"},{"issue":"9747","key":"9663_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(10)61537-1","volume":"376","author":"EM Krupitsky","year":"2010","unstructured":"Krupitsky EM, Woody G, Zvartau E, O\u2019Brien C (2010) Addiction treatment in Russia. Lancet 376(9747):1145","journal-title":"Lancet"},{"issue":"4","key":"9663_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2217\/pmt.12.26","volume":"2","author":"W Ling","year":"2012","unstructured":"Ling W (2012) Buprenorphine implant for opioid addiction. Pain Manag 2(4):345\u2013350. doi: 10.2217\/pmt.12.26","journal-title":"Pain Manag"},{"key":"9663_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/archpsyc.1978.01770270095009","volume":"35","author":"W Ling","year":"1978","unstructured":"Ling W, Klett CJ, Gillis RD (1978) A cooperative clinical study of methadyl acetate. Arch Gen Psychiatry 35:345\u2013353","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"9663_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/02791072.1994.10472259","volume":"26","author":"W Ling","year":"1994","unstructured":"Ling W, Rawson RA, Compton MA (1994) Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs 26(2):119\u2013128","journal-title":"J Psychoactive Drugs"},{"key":"9663_CR19","doi-asserted-by":"crossref","unstructured":"Ling W, Rawson RA, Anglin MD (2003) Pharmacology, practice, and politics: A tale of two opiate pharmacotherapies. In: Sorensen JL, Rawson RA, Guydish J, Zweben LE (eds) Drug abuse treatment through through collaboration: Practice and research partnerships that work, p. 107\u20131190 Wash. D.C. American Psychological Association","DOI":"10.1037\/10491-007"},{"issue":"10","key":"9663_CR20","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/add.12266","volume":"108","author":"W Ling","year":"2013","unstructured":"Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J (2013) Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 108(10):1788\u20131798. doi: 10.1111\/add.12266","journal-title":"Addiction"},{"key":"9663_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","volume":"93","author":"L Marsch","year":"1998","unstructured":"Marsch L (1998) The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 93:515\u2013532","journal-title":"Addiction"},{"key":"9663_CR22","doi-asserted-by":"crossref","unstructured":"Mattick RP, Kimber J, Breen C, Davoli M (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Rev. CD 002207","DOI":"10.1002\/14651858.CD002207.pub3"},{"key":"9663_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.euroneuro.2005.11.001","volume":"16","author":"HG Roozen","year":"2006","unstructured":"Roozen HG, de Waart R, van der Windt DAWM, van den Brink W, de Jong CAJ, Kerkhof AJFM (2006) A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol 16:311\u2013323","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"9663_CR24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","volume":"274","author":"SL Walsh","year":"1995","unstructured":"Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274(1):361\u2013372","journal-title":"J Pharmacol Exp Ther"},{"key":"9663_CR25","doi-asserted-by":"crossref","unstructured":"West S, Keri K, O'Neal K, Graham C (2000) A meta-analysis comparing the effectiveness of buprenorphine and methadone, J Subst Abu, Volume 12, Issue 4, Winter, pages 405-414.","DOI":"10.1016\/S0899-3289(01)00054-2"},{"key":"9663_CR26","doi-asserted-by":"publisher","unstructured":"Woody GE, Krupitsky E., Zvartau E (2016) Antagonist models for relapse prevention and reducing HIV risk. doi: 10.1007\/s11481-016-9659-8","DOI":"10.1007\/s11481-016-9659-8"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-016-9663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11481-016-9663-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-016-9663-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-016-9663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:39:47Z","timestamp":1748817587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11481-016-9663-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,23]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["9663"],"URL":"https:\/\/doi.org\/10.1007\/s11481-016-9663-z","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"value":"1557-1890","type":"print"},{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,23]]},"assertion":[{"value":"15 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"NIDA, PCORI, Indivior Inc.; Alkermes Inc., Braeburn Pharm. Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Grants and Research Support"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Directorship"}},{"value":"None","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Stocks and Options"}}]}}